Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019158 (hepatitis)
 30,205 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

An enzyme immuno assay kit has been developed to detect anti-HIV antibody in urine. In order to examine the clinical utility of the kit, 1333 urine samples were assayed. These samples consisted of 233 urine samples from HIV infected patients, 472 samples from HIV uninfected patients including 203 samples from patients with urogenital diseases, and 628 samples from normal subjects. Anti-HIV antibodies were detected in all the urine samples from HIV infected patients, and the diagnostic sensitivity for HIV infection was 100% with no false negative cases. A variety of anti-HIV antibody titers were found in the urine samples from HIV infected patients. However, no significant differences were found in the distribution patterns of urinary anti-HIV antibody titers among AC, ARC and AIDS patients. False positives were determined in only five samples in 628 healthy subjects (0.8%), one in 19 patients with hepatitis (5.3%), one in 45 patients with hemophilia (2.2%) and two in 105 pregnant women (1.9%). The antibody titers of all the false positive samples in these groups were less than the cut-off index multiplied by two. However, relatively high positive rates were demonstrated in the samples from urogenital diseases (11.8%), diabetes mellitus (20.0%) and auto-immune diseases (7.3%). False positive results were found to be directly correlated to the protein concentration of urinary protein, especially the immunoglobulin concentration in urine. The assay system was also evaluated by various reproducibility tests performed by different operators at different laboratories. The test results were satisfactory.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:[Clinical usefulness of urinary anti HIV antibody test--a large scale study from 11 institutes in Japan]. 774 30

The experimental evidence available for animal and plant RNA viruses, as well as other RNA genetic elements (viroids, satellites, retroelements, etc.), reinforces the view that many different types of genetic alterations may occur during RNA genome replication. This is fundamentally because of infidelity of genome replication and large population sizes. Homologous and heterologous recombination, as well as gene reassortments occur frequently during replication of retroviruses and most riboviruses, especially those that use enzymes with limited processivity. Following the generation of variant genomes, selection, which is dependent on environmental parameters in ways that are poorly understood, sorts out those genome fits enough to generate viable quasispecies. Chance events can also be destabilizing, as illustrated by recent results on fitness loss and other phenotypic changes accompanying bottleneck transmission. Variation, selection, and random sampling of genomes occur continuously and unavoidably during virus evolution. Evolution of RNA viruses is largely unpredictable because of the stochastic nature of mutation and recombination events, as well as the subtle effects of chance transmission events and host/environmental factors. Among environmental factors, alterations resulting from human intervention (deforestation, agricultural activities, global climatic changes, etc.) may alter dispersal patterns and provide new adaptive possibilities to viral quasispecies. Current understanding of RNA virus evolution suggests several strategies to control and diagnose viral diseases. The new generation of chemically defined vaccines and diagnostic reagents (monoclonal antibodies, peptide antigens, oligonucleotides for polymerase chain reaction amplification, etc.) may be adequate to prevent disease and detect some or even most of the circulating quasispecies of any given RNA pathogen. However, the dynamics of viral quasispecies mandate careful consideration of those reagents to be incorporated into diagnostic kits. Broadening diagnosis without jeopardizing specificity of detection will be challenging. There is a finite probability (impossible to quantify at present) that a defined vaccine may promote selection of escape mutants or a particular diagnostic kit may fail to detect a viral pathogen. Of particular concern are the potential long-term effects of weak selective pressures that may initially go unnoticed. Variant viruses resulting from evolutionary pressure imposed by vaccines or drugs may insidiously and gradually replace previous quasispecies. The great potential for variation and phenotypic diversity of some important RNA virus pathogens (human immunodeficiency virus, the hepatitis viruses, the newly recognized human hantaviruses, etc.) has become clear. Prevention and therapy should rely on multicomponent vaccines and antiviral agents to address the complexity of RNA quasispecies mutant spectra.(ABSTRACT TRUNCATED AT 400 WORDS)
 ...
PMID:RNA virus quasispecies: significance for viral disease and epidemiology. 782 89

The aim of this study is to investigate whether hepatitis B e antigen (HBeAg) reactivity can be detected on formalin-fixed, paraffin-embedded liver tissue, and whether immunohistochemical detection of intrahepatic HBeAg may help to distinguish between "wild-type" and "eminus" hepatitis B virus (HBV) infection. Liver biopsy specimens were analyzed from 27 patients with chronic type B hepatitis: 12 patients had serum HBeAg (group A), and 15 patients were anti-HBe positive (group B). Part of each biopsy fragment was processed for histologic and immunohistochemical studies, and a part was used for HBV-DNA analysis. Dewaxed sections from each specimen were tested with a specific monoclonal anti-HBe antibody; then a Biotin-Streptavidin kit was used as detection system. HBeAg was revealed in 10 of 12 cases of group A and in 6 of the 15 cases of group B. Pre-core region of HBV genomes, isolated from each biopsy specimen, was analyzed by direct sequencing: 10 cases of group A were found to be infected by wild-type HBV alone and 2 cases by both wild and e-minus HBV types. In group B, all the 6 cases with intrahepatic HBeAg reactivity were found to be infected by mixed viral population, whereas the 9 cases negative for such reactivity were found to be infected by e-minus HBV alone. These results show that HBeAg can be detected in formalin-fixed, paraffin-embedded liver specimens, and the method is sensitive and specific. Because the presence of HBeAg in the liver indicates a wild-type HBV infection, and the lack of detection of such antigen in the hepatocytes of anti-HBe positive subjects correlates with unmixed e-minus HBV infection, the authors conclude that this technique is a useful tool for recognizing the viral strains that infect patients with chronic type B hepatitis.
 ...
PMID:Hepatitis B E antigen detection in formalin-fixed liver biopsy specimens. A tool to investigate wild-type and E-minus variant HBV infection. 785 54

In Japan, the major transfusion-associated disease is non-A, non-B hepatitis. We studied the relationship between transfusion history and blood donor antibodies to hepatitis C virus (HCV). The positive rate of antibodies to the HCV nonstructural protein (c100-3) depended on age and the time elapsed since transfusion. The anti-c100-3 ratio for subjects with transfusions made prior to 20 years ago was high. One quarter century ago, a change occurred in national blood policy from paid to non-paid voluntary donations. We also have studied the anti-HCV positive rate among donors with prior transfusion using a second generation HCV test kit which includes anti-HCV core antibody detection. The anti-HCV positive rate for the second generation test was higher than that for the anti-c100-3 test. Introduction of the second generation test is therefore more useful in screening than the anti-c100-3 test for blood programs.
 ...
PMID:The effect of prior transfusion history on blood donor anti-hepatitis C virus antibody. 788 69

A synthetic HDAg 27 peptide which was selected and designed by the authors and synthesised by Shanghai Institute of Biochemistry, Chinese Academy of Science was used with ELISA method to detect serum anti HD in HBV infected subjects in Chongqing. Anti HD was positive in one of 300 blood donors and was negative in all of 113 cases of hepatitis A and 58 cases of hepatitis non-B. Anti HD was positive in 106 out of 882 cases with positive HBV marker (12.02%), among which anti HD was positive in 3.17% (13/410) of HBsAg carrier, 14.4% (11/76) of acute hepatitis, 7.6% (1/13) of chronic persistent hepatitis, 17.68% (22/121) of chronic active hepatitis, 19.77% (17/86) of severe hepatitis, 29.49% (23/78) of liver cancer and 19.39% (19/98) of primary hepatic cancer. These results coincided with those of previous reports. The coincidence rate was 94.9% (74/78) when compared with Abbott EIA kit. When the natural HDAg was used to compete anti HD in four anti HD positive and two anti HD negative serum specimens, anti HD was negative in all specimens. It is shown that the HDAg 27 peptide has natural HDAg activity capable of being recognized by natural anti HD and is a new diagnostic agent being more simple, save, stable and reliable.
 ...
PMID:[Application of synthetic 27 oligopeptide of HDV antigen for detecting serum anti-HD in HBV infected subjects in Chongqing]. 795 61

Recently, the CA 19-9-MP-Mitsui kit (MP-kit) by a sandwich enzyme immunoassay using two mouse monoclonal antibodies of C192 and C241 for the determination of CA 19-9 was developed by Mitsui Pharmaceutical Co., Ltd.. We carried out basic and clinical studies of MP-kit for the serum CA 19-9 in comparison with the Immunoclone CA 19-9 EIA kit (I-kit) which was provided by Fuji-Rebio Company. It was found that MP-kit appeared to have excellent reproducibility with high sensitivity and specificity for CA 19-9. Furthermore, the coefficient of positive correlation was as high as 0.92 in serum CA 19-9 level between MP-kit and I-kit in the determination of serum CA 19-9 in 67 cases by each of two kits. On the other hand, with two kits, it was found that employment of a cut off value more than 70 U/ml brought a highest diagnostic efficiency for pancreatic and bile duct cancers, while employment of a cut off value of 37 U/ml which was used routinely resulted in a high false positive incidence, particularly in liver cirrhosis or hepatitis. From the results, it is concluded that a pertinent cut off value of CA 19-9 in serum was about 70 U/ml and MP-kit was available for determination of CA 19-9 in serum such as the other known kits on the market for CA 19-9.
 ...
PMID:[A basic and clinical study of CA 19-9-MP-Mitsui kit for determination of CA 19-9]. 799 14

In serum of patients with chronic hepatitis B (HB) in the stage of active viral replication HBsAg/IgM complexes were detected. Using a commercial kit AU-IGM-K Sorin Biomedica HBsAg/IgM complexes in 136 patients with chronic HB and cirrhosis of the liver were examined, incl. 89 men, 42 women and 5 children, mean age 48 +/- 17 years. With regard to the results of the serological examination for HB virus (HBV) markers the results in 54 patients with positive HBeAg and HBsAg in serum (group 1) were compared with 68 patients with positive HBsAg only (group 2) and with 14 patients with positive antibodies against HBV or unrelated to HBV (group 3). The mean positivity index of HBsAg/IgM complexes in group 1, 2 and 3 was 9.89, 1.85 and 0.50, respectively. The results suggest a significant predominance of HBsAg/IgM complexes in patients during the stage of active viral replication with positive HBeAg in serum, as compared with patients without HBeAg (p = 0.001) and the control group (p = 0.001). A similar significant difference between groups was found as regards to ALT and AST activities. We conclude that in patients with chronic HBeAg positive hepatitis and a moderately elevated transaminase activity usually also HBsAg/IgM complexes, which are closely correlated with HBeAg, are positive.
 ...
PMID:Clinical importance of assessment of HBsAg/IgM complexes in chronic hepatitis B. 810 61

Recently, with an available serological hepatitis E virus diagnostic kit, the prevalence of IgG antibody to hepatitis E virus among Chinese subjects in Taiwan was evaluated by means of a solid-phase enzyme-linked immunoassay based on two recombinant hepatitis E virus antigens. The overall prevalence of hepatitis E virus antibody was 10.7% among 384 healthy subjects older than 20 yr but only 0.3% among 600 schoolchildren and young adolescents younger than 20 yr (p < 0.0001). Serial serum samples from 32 hepatitis E virus antibody-positive healthy subjects showed 84% of them to have antibodies persisting more than 3 to 8 yr. Among patients with viral hepatitis, IgG hepatitis E virus antibody was detected in 10% of 10 patients with acute hepatitis A, in 9.5% of 63 patients with acute hepatitis B and in 13.9% of 36 patients with acute posttransfusion hepatitis C. Of 77 patients with sporadic non-A, non-B hepatitis, IgG hepatitis E virus antibody was detected in 18.9% of 53 patients positive for antibody to hepatitis C virus and in 45.8% of 24 patients negative for hepatitis C virus antibody (p < 0.03). Most of our hepatitis E virus antibody-positive normal subjects and patients had never been abroad. These findings demonstrate that sporadic or subclinical hepatitis E virus infections also exist among the Chinese subjects in Taiwan. Hepatitis E virus infection may play an important role in patients with hepatitis C virus antibody-negative sporadic non-A, non-B hepatitis. IgG hepatitis E virus antibody in the sera of normal subjects may last for more than 8 yr.
 ...
PMID:Seroprevalence of antibody to hepatitis E virus among Chinese subjects in Taiwan. 813 58

In order to manage the increased workload resulting from post vaccination hepatitis antibody testing of health care workers, the anti-hepatitis B ELISA assay ETI-AB-AUK (Sorin Biomedica), adapted for quantification using standards available as an addition to the qualitative kit assay (ABAU-STD-SET, (Sorin Biomedica)) and a sample pre-dilution step, was compared with a fully automated microparticle enzyme immunoassay IMX AUSAB (Abbott Laboratories), and a semi-automated enhanced luminescence system (Amerlite Amersham, now Kodak). Seventy-eight samples were concurrently tested and analysed statistically using a Regression Coefficient computer package (Apple Mackintosh Cricket). Good quantitative agreement was observed with ELISA vs IMX giving a linear correlation coefficient (r = 0.96). The linear correlation coefficient for ELISA vs Amerlite was r = 0.77. This study validates the use of the automated IMX system and allows the comparison of IMX results with previous 'semi-quantitative' ELISA results when longitudinally assessing patients response to a recombinant hepatitis B vaccine.
 ...
PMID:Comparison of an ELISA system for the quantification of hepatitis B antibody with an automated and a semi-automated system. 827 Jun 56

The authors isolated a specific cDNA clone (clone 14) for non-A, non-B hepatitis virus infection. In this study, we developed an enzyme-linked immunosorbent assay (ELISA) using a synthetic oligopeptide encoded by clone 14 and examined its usefulness for detecting hepatitis C virus (HCV) antibody in 181 patients with chronic NANB hepatitis, 88 with cirrhosis and 24 with hepatocellular carcinoma associated with NANB hepatitis virus. Anti-clone 14 antibody was detected in 75% of patients with chronic NANB hepatitis, 57% of cirrhotic patients and 58% hepatocellular carcinoma patients. Anticlone 14 and anti-C-100 antibody assayed using a commercial kit were found in serum from 199 (69%) and 205 (70%) of these 294 patients, respectively. Approximately 85% of the patients showed the presence of anticlone 14 and/or anti-C-100 antibodies. We compared the presence of these antibodies and the second generation anti-HCV antibody using ELISA and HCV RNA by the polymerase chain reaction assay, in the same blood samples from 49 patients with chronic liver disease who had anti-clone 14 and/or anti-C-100 antibody. HCV RNA was detected in 38 of 40 (95%) plasma samples containing anti-clone 14 antibody, the prevalence of which was similar to that for anti-C-100 antibody (41/42, 98%) and the second generation anti-HCV antibody (46/47, 98%). Furthermore, 6 of 7 plasma samples containing anti-clone 14 antibody and lacking anti-C-100 antibody were positive for the second generation anti-HCV antibody and HCV RNA.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Development of a specific enzyme-linked immunosorbent assay for the hepatitis C virus antibody using clone 14. 838 40


<< Previous 1 2 3 4 5 6 7 8 9 Next >>